1-5 of 5
Authors: Wolfgang Tome
Journal Article
CTNI-48. SURVIVAL, TOXICITY, AND PATIENT REPORTED QOL OUTCOMES FOLLOWING PULSED REDUCED DOSE RATE RE-IRRADIATION WITH CONCURRENT BEVACIZUMAB FOR RECURRENT GRADE 4 GLIOMAS: RESULTS OF A PHASE II STUDY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v86, https://doi.org/10.1093/neuonc/noad179.0330
Published: 10 November 2023
Journal Article
ACTR-50. PRESERVATION OF NEUROCOGNITIVE FUNCTION & PATIENT-REPORTED SYMPTOMS WITH HIPPOCAMPAL AVOIDANCE (HA) DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: LONG-TERM RESULTS OF NRG ONCOLOGY CC001
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Pages vi24–vi25, https://doi.org/10.1093/neuonc/noz175.092
Published: 11 November 2019
Journal Article
RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM)
Neuro-Oncology Advances, Volume 1, Issue Supplement_1, August 2019, Pages i23–i24, https://doi.org/10.1093/noajnl/vdz014.104
Published: 12 August 2019
Journal Article
BSCI-18. ABLATION OF Csf2 MITIGATES RADIATION-INDUCED NEUROCOGNITIVE DECLINE INDEPENDENT OF HIPPOCAMPAL NEUROGENESIS
Neuro-Oncology Advances, Volume 1, Issue Supplement_1, August 2019, Page i4, https://doi.org/10.1093/noajnl/vdz014.016
Published: 12 August 2019
Journal Article
NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi172, https://doi.org/10.1093/neuonc/noy148.716
Published: 05 November 2018
